Replimune (REPL)

[morokoy]

From Chat GPT -

Replimune’s investigational therapy RP1 (vusolimogene oderparepvec) combined with nivolumab is on track for a definitive FDA decision by July 22, 2025, under a Priority Review designation
ir.replimune.com

Here are the key points affecting its approval chances:

✅ Strong FDA Support & Smooth Pathway
Breakthrough Therapy designation and Priority Review signals prioritize expedited review based on strong efficacy in high-need setting
.
No Advisory Committee planned and no review issues flagged — an encouraging sign that the FDA doesn’t foresee major safety or requirement hurdles

Manufacturing inspections and late-cycle review are complete with all processes on track

📊 Supporting Clinical Data
Phase 2 IGNYTE trial in anti–PD-1 refractory melanoma showed:

33.6% objective response rate (ORR), including 15% complete responses

Confirmed durable responses (median duration ~21.6 months)

Strong 1-, 2-, and 3-year survival rates of 75%, 63%, and 55% respectively

Safety profile was manageable: mostly grade 1/2 events, ~13% grade 3+; no treatment-related deaths

🧠 Analyst and Industry Outlook
Analysts view the lack of Advisory Committee and clean review process as de-risking approval

As of March?31, 2025, Replimune held nearly $484million in cash, supporting their commercial readiness (est. 13,000 eligible U.S. patients annually, ~80% eligible for RP1)

🔎 Approval Likelihood: Bullish But Not Guaranteed
Likely scenario:
FDA approves RP1 + nivolumab by July 22, 2025, given priority status, solid Phase 2 data, no AdComm, and regulatory prep.
Potential risks:
Issues could arise in late-stage confirmatory data or existing manufacturing concerns, but none are evident so far.

📝 In Summary
All current signs point toward a high probability of FDA approval by late July 2025. Breakthrough/priority designations, lack of advisory meeting, favorable clinical results, and no red flags from the FDA are powerful indicators of a smooth approval process.

🎯 Final Take: Replimune is strongly positioned for RP1 approval this summer — watch for the July 22 decision.